Stocks Alert: OneMain Holdings Inc (NYSE:OMF), Amarin Corporation plc (ADR) (NASDAQ:AMRN)

On Monday, Shares of OneMain Holdings Inc (NYSE:OMF), added 5.82% and closed at $20.53 in the last trading session. The last trading range of the stock ranges between $19.63 and $20.69. OneMain Holdings, Inc., through its auxiliaries, provides consumer finance and insurance products and services. It provides personal loans secured by consumer household goods, and other personal property; unsecured loans; and loans secured by subordinate residential real estate mortgages. The company also offers auto loans for purchasing new vehicles, in addition to to pay off the existing auto loans. In addition, it writes credit life, disability, credit involuntary unemployment, and credit related property and casualty insurance products, in addition to non-credit insurance products; and offers home and auto membership plans. As of April 27, 2016, it offered services at 1,800 branches in 43 states. The company was formerly known as Springleaf Holdings, Inc. and changed its name to OneMain Holdings, Inc. in November 2015.

Amarin Corporation plc (ADR) (NASDAQ:AMRN), jumped 3.80% and closed at $3.28 in the last trading session. The last trading range of the stock ranges between $3.13 and $3.33. The company’s Market capitalization is $908.44 million with the total Outstanding Shares of 269.95 million. Amarin Corporation plc (AMRN) recently declared an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of Vascepa® (icosapent ethyl) in statin-treated women with persistent high triglyceride levels.

The presentation of additional data from the ANCHOR study showed, consistent with overall study results, that prescription pure EPA Vascepa® (icosapent ethyl) reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers in a subgroup of statin-treated women with persistent high triglycerides. The post hoc analysis supporting the efficacy of pure, prescription icosapent ethyl in this patient population was presented as an oral abstract (#309) titled, “Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Women With Persistent High Triglycerides: Results From the ANCHOR Study.”

Leave a Reply

Your email address will not be published. Required fields are marked *